Sellas Life Sciences Group Inc
SLS1.630USD
+0.020+1.24%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
163.60MMarket Cap
LossP/E TTM
More Details of Sellas Life Sciences Group Inc Company
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
Company Info
Ticker SymbolSLS
Company nameSellas Life Sciences Group Inc
IPO dateMar 12, 2008
CEODr. Angelos M. Stergiou, M.D.
Number of employees15
Security typeOrdinary Share
Fiscal year-endMar 12
Address7 Times Square
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10036
Phone16462005278
Websitehttps://www.sellaslifesciences.com/
Ticker SymbolSLS
IPO dateMar 12, 2008
CEODr. Angelos M. Stergiou, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Dr. David A. Scheinberg, M.D., Ph.D.
Dr. David A. Scheinberg, M.D., Ph.D.
Independent Director
Independent Director
10.58K
-38.05%
Mr. John W. Varian
Mr. John W. Varian
Independent Chairman of the Board
Independent Chairman of the Board
10.40K
-38.46%
Name
Name/Position
Position
Shareholding
Change
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
6.32%
BlackRock Institutional Trust Company, N.A.
3.96%
Marshall Wace LLP
2.58%
Geode Capital Management, L.L.C.
2.09%
Susquehanna International Group, LLP
1.41%
Other
83.64%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
6.32%
BlackRock Institutional Trust Company, N.A.
3.96%
Marshall Wace LLP
2.58%
Geode Capital Management, L.L.C.
2.09%
Susquehanna International Group, LLP
1.41%
Other
83.64%
Shareholder Types
Shareholders
Proportion
Investment Advisor
14.79%
Investment Advisor/Hedge Fund
7.19%
Hedge Fund
2.07%
Research Firm
1.16%
Individual Investor
0.32%
Bank and Trust
0.13%
Pension Fund
0.10%
Venture Capital
0.07%
Insurance Company
0.03%
Other
74.13%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
100
16.82M
16.86%
+5.40M
2025Q1
95
15.37M
15.79%
+4.85M
2024Q4
82
6.32M
8.71%
-3.29M
2024Q3
79
5.54M
8.62%
-2.91M
2024Q2
81
6.60M
15.25%
-2.78M
2024Q1
80
10.46M
22.59%
+5.00M
2023Q4
78
5.95M
19.06%
+1.91M
2023Q3
79
3.15M
11.52%
-1.61M
2023Q2
83
3.51M
12.82%
-1.46M
2023Q1
86
3.47M
12.66%
-413.28K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.84M
2.85%
+546.46K
+23.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
436.33K
0.44%
+3.52K
+0.81%
Mar 31, 2025
Geode Capital Management, L.L.C.
820.44K
0.82%
+86.89K
+11.85%
Mar 31, 2025
Susquehanna International Group, LLP
688.70K
0.69%
+688.70K
--
Mar 31, 2025
State Street Global Advisors (US)
277.03K
0.28%
+49.30K
+21.65%
Mar 31, 2025
Northern Trust Investments, Inc.
164.39K
0.16%
+29.70K
+22.05%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
